J. Mendy

发表

Pre-Clinical Evaluation of a Replication-Competent Recombinant Adenovirus Serotype 4 Vaccine Expressing Influenza H5 Hemagglutinin

J. Avanzini, J. Alexander, M. Newman, 2012, PloS one.

Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge

E. Harris, J. Avanzini, Jayavani Aruri, 2017, EBioMedicine.

Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge

E. Harris, J. Alexander, Diego A. Espinosa, 2022, PLoS neglected tropical diseases.

Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.

J. Ledgerwood, Kelly L. Warfield, L. Bedell, 2022, The Lancet. Infectious diseases.

Peptidoglycan recognition protein expression in mouse Peyer's Patch follicle associated epithelium suggests functional specialization.

David J Brayden, D. Lo, J. Dickerson, 2003, Cellular immunology.

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C

H. Liao, B. Haynes, D. Montefiori, 2013, PloS one.

Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus

P. Shabram, J. Alexander, J. Julander, 2021, PLoS neglected tropical diseases.

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge

H. Liao, B. Haynes, N. Haigwood, 2017, Journal of Virology.

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge

N. Haigwood, H. Robins, M. Axthelm, 2021, Frontiers in Immunology.

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

J. Mascola, T. Pierson, R. Koup, 2020, JAMA.

A Phase 1 Two-Arm, Randomized, Double-Blind, Active-Controlled Study of Live, Oral Plasmid-Derived Adenovirus Type 4 and Type 7 Vaccines in Seronegative Adults

I. Maljkovic Berry, P. Shabram, N. Karasavvas, 2023, Vaccines.